M. Mayrand

Marie-Hélène Mayrand is a professor in the departments of Obstetrics and Gynecology and Social and Preventive Medicine at the Université de Montréal, where she completed her medical degree and specialty training. She completed her PhD in Epidemiology at McGill University, focusing the evaluation of cervical cancer screening strategies. Her professional work spans clinical, biomedical research and public health aspects of cancer prevention. She practices colposcopy at the CHUM. She has led large multi-center trials focusing on more efficient prevention of cervical cancer through innovative screening/treatment algorithms and vaccination schedules. Dr Mayrand has worked with professional and public health organizations to draft clinical guidelines, provide government reports/advice, and move public health and clinical practice in line with the best available evidence.

Author Of 2 Presentations

Introduction (ID 721)

Presenter
Lecture Time
12:45 PM - 12:50 PM

Chairperson’s closing remarks (ID 725)

Presenter
Lecture Time
01:45 PM - 01:55 PM

Presenter of 2 Presentations

Introduction (ID 721)

Presenter
Lecture Time
12:45 PM - 12:50 PM

Chairperson’s closing remarks (ID 725)

Presenter
Lecture Time
01:45 PM - 01:55 PM

Moderator of 1 Session

Session Type
Industry Sponsored Session
Date
Wed, Nov 17, 2021
Session Time
12:45 PM - 02:15 PM
Chair(s)
Session Description
Screening Smarter in the Post-Pandemic Era: The Clinical Utility of Extended Genotyping and Self-Collection - Supported by BD

Session Description:

Screening Smarter in the Post-Pandemic Era: The Clinical Utility of Extended Genotyping and Self-Collection- Supported by BD Session Description: Session Description: The title of the BD Symposium will be, “Screening Smarter in the Post-Pandemic Era: The Clinical Utility of Extended Genotyping and Self-Collection”. The moderator, Marie-Hélène Mayrand, MD, PhD, FRCSC of the Université de Montréal will introduce the symposium and the three symposium speakers. Jesper Bonde, Ph.D., head of the Molecular Pathology Laboratory, Hvidovre Hospital, Denmark will present scientific evidence from a clinical validation of the high-throughput BD COR™ System and discuss the Danish experience with Primary HPV screening implementation. Karena Volesky, MS of McGill University, will present evidence from the Canadian Cervical Cancer Screening Trial (CCCaST), including clinical performance of the BD Onclarity extended genotyping assay for the management of women positive for HPV. Jack Cuzick, PhD, FRS, FMedSci, FRCP(hon) of the Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention Centre for Cancer Prevention, Queen Mary University, London, will provide evidence regarding self-collection for Primary HPV screening, utility of extended genotyping and comment on the future of cervical cancer screening. Dr. Mayrand will give her perspective summation of the three presentations before fielding questions from the audience for the panel.

Session Icon
Pre-Recorded with Live Q&A